Independently scored across 5 dimensions · Updated weekly · No paid placements
Drug-vs-drug · Updated 12 May 2026

Compounded semaglutide vs Wegovy: which weight loss drug is better in 2026?

Same active molecule (semaglutide), different regulatory pathways. Wegovy is the FDA-approved branded version manufactured by Novo Nordisk. Compounded semaglutide is prepared by a 503A pharmacy under prescription. The savings are 50-80% in cash-pay; the cost is loss of FDA new-drug-approval oversight and insurance coverage.

The seven-row TL;DR

For each dimension where one drug clearly wins, we name the winner. Where the answer is "depends on your situation," the verdict text below the table explains why.

DimensionWhat the data saysWinner
Active ingredientSemaglutide in bothTie
FDA approval as drug productWegovy yes; compounded noWegovy
Cash-pay cost$99-$249/mo (compounded) vs $199-$499/mo (NovoCare)Compounded
Insurance coverageWegovy with PA; compounded never coveredWegovy
Supply continuity in 2025-2026Wegovy stable; compounded semaglutide narrowed but holdingWegovy
Manufacturing oversightFDA cGMP for Wegovy; state-board oversight for 503AWegovy
Prescriber accessMost US weight loss telehealth programs prescribe bothTie

Verdict

If you can access Wegovy through insurance with prior authorization, choose Wegovy. The full FDA oversight, manufacturing consistency, and stable supply chain are worth the trade against compounded's lower cash price. If you cannot access insurance and NovoCare's $199-$499 is out of reach, compounded semaglutide via a transparent 503A program (Mochi, Noom Med microdose, Henry Meds) is a defensible second choice. The molecule is the same; the regulatory pathway is not.

Trial efficacy compared

The headline numbers are not from the same study, so direct comparison is approximate. The 2024 SURMOUNT-5 trial directly compared tirzepatide to semaglutide and found tirzepatide produced greater weight loss across all dose comparisons, validating the cross-trial signal.

Compounded semaglutideWegovy
Registration trialSTEP-1 (parent molecule, Wegovy) (NEJM, 2021)STEP-1 (NEJM, 2021)
Duration68 weeks68 weeks
Mean weight loss (max dose)14.9%14.9%
Effect vs placebo12.4 pp12.4 pp
Patients losing ≥5%86.4%86.4%
Patients losing ≥15%50.5%50.5%

2026 cash-pay cost compared

Both manufacturers run direct-to-consumer cash channels (NovoCare for Compounded semaglutide, LillyDirect for Wegovy) which are dramatically cheaper than the retail pharmacy cash price. Telehealth programs add a membership fee on top of medication cost.

ChannelCompounded semaglutideWegovy
Retail cashNot sold at retail; cash-pay through telehealth programs only$1,349/mo
Manufacturer DTC$99-$249/mo via telehealth programs (Mochi $99, Found $159, Noom microdose $99)$199-$499/mo via NovoCare
With insurance + PANot covered by insurance. Compounded medications are not eligible for insurance reimbursement as drug products.$25-$50/mo with prior authorization
CompoundedCash-pay only by definition. Pricing varies $99-$249/mo depending on program.$99-$249/mo via 503A pharmacies

When to choose Compounded semaglutide

Choose compounded semaglutide if: (1) you have no insurance coverage and NovoCare's lowest tier is still out of reach for your budget; (2) you have selected a program with a transparent and stable 503A pharmacy partnership (Mochi or Noom microdose are the cleanest in our chart); (3) you understand the regulatory environment may tighten further; (4) you have a Plan B if the program loses pharmacy partnership mid-treatment.

When to choose Wegovy

Choose Wegovy if: (1) your insurance covers it (most commercial plans do for BMI ≥30 with PA); (2) NovoCare's $199 starter dose is sustainable; (3) you want manufacturing oversight under FDA cGMP rather than state-board oversight; (4) you want supply continuity that doesn't depend on a single 503A pharmacy partnership; (5) you want the option to switch programs without changing medication source.

Programs that prescribe each

Top Compounded semaglutide programs

Top Wegovy programs

FAQ

Is compounded semaglutide the same as Wegovy?
Same active molecule (semaglutide); different regulatory pathway. Wegovy is FDA-approved as a drug product manufactured under cGMP by Novo Nordisk. Compounded semaglutide is prepared by a 503A pharmacy under individual prescription, not FDA-approved as a drug product. The molecules are chemically identical; the manufacturing oversight, supply chain, and regulatory standing are not.
Is compounded semaglutide legal?
Yes, under section 503A of the Federal Food, Drug, and Cosmetic Act, when prepared for an individual patient under valid prescription. Compounding existed before GLP-1s and serves a legitimate role in drug supply (allergies to inactive ingredients, dosing adjustments, etc.). The category-wide volume of compounded GLP-1 has prompted increased FDA enforcement attention since the semaglutide shortage was declared resolved in October 2024.
Will my insurance cover compounded semaglutide?
Almost never. Compounded medications are not eligible for insurance reimbursement as drug products in the way FDA-approved drugs are. A small number of insurance plans reimburse compounded medications under their compounding benefit, but GLP-1 specifically is rarely covered.
What if my program's compounded supply is cut off?
This is the central practical risk in 2026. Programs vary in their continuity planning. The cleanest programs have multiple 503A partnerships; some are pre-positioning patients to switch to NovoCare or Wegovy if compounded supply ends. Ask your program directly about Plan B before committing.
Can I switch from compounded to Wegovy mid-treatment?
Yes. Most prescribers will continue you on the same dose level (e.g., compounded 1.0mg to Wegovy 1.0mg) and titrate from there. The switch is straightforward clinically; the friction is administrative (insurance PA, program enrollment) and budgetary (Wegovy with insurance is typically much cheaper than compounded; without insurance, NovoCare may be more or less depending on dose tier).

Read the full drug profiles

Editorial disclosure

GLP Chart is an editorial comparison site. We do not dispense, prescribe, or fulfill medications. Trial data is from the cited NEJM publications. Pricing reflects publicly verified rates as of 12 May 2026. Talk to a licensed clinician about which medication is appropriate for you.

Why you can trust GLP Chart Same scoring framework applied to every program. No paid placements. No removal of unfavorable information at advertiser request. Pricing is pulled from each provider's public-facing page weekly.
Independent comparison site. Not a medical provider, telehealth platform, or pharmacy. Information is educational, not medical advice. Always consult a licensed clinician. We may earn a commission on partner links at no cost to you.